Back to Search
Start Over
Effect of felbamate on clobazam and its metabolite kinetics in patients with epilepsy.
- Source :
-
Therapeutic drug monitoring [Ther Drug Monit] 1999 Dec; Vol. 21 (6), pp. 604-8. - Publication Year :
- 1999
-
Abstract
- The authors report preliminary findings on the effect of the new generation antiepileptic drug (AED) felbamate (FBM) on steady state plasma concentrations of clobazam (CLB), a benzodiazepine (frequently used as add-on therapy in patients with refractory epilepsy) and its active metabolite n-desmethyl-clobazam (N-CLB). The authors prospectively collected plasma samples from 66 children and adults with epilepsy receiving chronic CLB therapy. On the basis of concomitant AEDs, patients were divided into three subgroups otherwise comparable for age and weight-adjusted daily dose of CLB: group A (n = 22), receiving CLB monotherapy or CLB plus AEDs without inducing properties of cytochrome P450 (CYP) metabolism, namely valproic acid (VPA) or lamotrigine (LTG); group B (n = 28), receiving CLB plus AED inducer polytherapy (carbamazepine, phenobarbital, phenytoin), even associated with VPA (n = 9) or LTG (n = 12); group C (n = 16), receiving CLB plus FBM, associated with AED inducers, VPA or LTG. Level to weight-adjusted dose ratio (L/D) of CLB in groups B and C was twofold lower compared to group A (p < 0.001). L/D of N-CLB was twofold higher in group B and fivefold in group C compared to group A (p < 0.00 1). The metabolite-to-parent drug ratio shifted from a median value of 2.8 in group A to 13 in group B, and up to 29 in patients receiving polytherapy with FBM (p < 0.001). These data confirm previous reports of a significant increase in CLB clearance in patients receiving AED inducers, leading to an accumulation of its main metabolite. They also provide novel evidence of a further marked increase in N-CLB plasma concentrations in patients receiving FBM cotherapy. From a clinical point of view, this finding should be kept in mind in explaining possible toxicity in patients on complex AED polytherapy. Furthermore, knowledge of the in vivo interaction between CLB and FBM could help in identifying the CYP isoforms involved in the metabolism of both CLB and N-CLB.
- Subjects :
- Adolescent
Adult
Anti-Anxiety Agents blood
Anti-Anxiety Agents therapeutic use
Anticonvulsants blood
Anticonvulsants therapeutic use
Carbamazepine pharmacology
Carbamazepine therapeutic use
Child
Child, Preschool
Clobazam
Cytochrome P-450 Enzyme System metabolism
Drug Therapy, Combination
Epilepsies, Partial drug therapy
Felbamate
Female
Humans
Lamotrigine
Male
Phenobarbital pharmacology
Phenobarbital therapeutic use
Phenylcarbamates
Phenytoin pharmacology
Phenytoin therapeutic use
Propylene Glycols therapeutic use
Prospective Studies
Triazines pharmacology
Triazines therapeutic use
Valproic Acid pharmacology
Valproic Acid therapeutic use
Anti-Anxiety Agents pharmacokinetics
Anticonvulsants pharmacokinetics
Benzodiazepines
Epilepsies, Partial metabolism
Propylene Glycols pharmacology
Subjects
Details
- Language :
- English
- ISSN :
- 0163-4356
- Volume :
- 21
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- Therapeutic drug monitoring
- Publication Type :
- Academic Journal
- Accession number :
- 10604819
- Full Text :
- https://doi.org/10.1097/00007691-199912000-00004